Patient Care

FOLR1 a target for CAR T therapy in C/G model of pediatric AML

11.24.22

FOLR1 a target for CAR T therapy in C/G model of pediatric AML

by ASTCT Science Highlights

Study Finds Lower Rates of CAR T Adverse Effects in Real-Word Settings Than in Clinical Trials

11.22.22

Study Finds Lower Rates of CAR T Adverse Effects in Real-Word Settings Than in Clinical Trials

by Eleanor Mayfield, ELS

“No Long-Term QOL Detriment” Due to CRS or NEs in TRANSCEND Trial

11.22.22

“No Long-Term QOL Detriment” Due to CRS or NEs in TRANSCEND Trial

by Eleanor Mayfield, ELS

Integration of Allogeneic CAR-T and HCT using PTCy in murine model

11.15.22

Integration of Allogeneic CAR-T and HCT using PTCy in murine model

by ASTCT Science Highlights

PRAME mTCRCAR T cell therapy in AML

10.27.22

PRAME mTCRCAR T cell therapy in AML

by ASTCT Science Highlights

Sequential T-cell Redirection Therapy in R/R MM

10.25.22

Sequential T-cell Redirection Therapy in R/R MM

by ASTCT Science Highlights

Third-party VST Early After allo-HSCT

09.26.22

Third-party VST Early After allo-HSCT

by ASTCT Science Highlights

Higher Doses of Tisagenlecleucel Associated with Improved Outcomes

09.15.22

Higher Doses of Tisagenlecleucel Associated with Improved Outcomes

by ASTCT Science Highlights

Mechanisms of Effector Development in CAR-T Products

09.06.22

Mechanisms of Effector Development in CAR-T Products

by ASTCT Science Highlights

THANK YOU TO OUR SPONSORS

Jansen Oncology

Legend Biotech